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IL-4 or B cell stimulating factor is a polypeptide that was originally described,
in murine models ofB cell response, as a costimulant with anti-IgM antibody for
the entry of resting B cells into the S phase of the cell cycle (1) . Recent studies have
shown that IL-4 is associated with multiple biologic activities . IL-4 increases the
expression of class II MHC molecules on resting B cells (2, 3) and promotes IgGl
and IgE production by LPS preactivated B cells (4, 5) . Although initially believed
to be principally active on B cells, IL-4 has been shown to act on normal T cells
(6, 7),T cell lines (7-9), mast cell lines (10), and hematopoietic lineage cells (11, 12) .
Recently, theisolationo£ acDNA sequence coding forhumanIL-4 hasbeen reported
(13) . Human IL-4 is able to promote the growth of activated normal B cells (14),
of activatedT cells (15), and to induce the expression ofCD23 antigen on normal
B cells (16) .
Monoclonal lymphocytes from B-type chronic lymphocytic leukemia (B-CLL) t
patients canrespond to some growth factors (17, 18). Theanalysis ofthis responsive-
ness is importantto define the pattern ofreactivity ofthese malignant cellsto physi-
ological signals . In addition, the use ofmonoclonal B cells frozen at a given stage
of differentiation and possibly arising from a discrete B cell subset may help in the
understanding of the effects of interleukins . This work was designed to define the
effects of IL-4 on these B-CLL lymphocytes . We thus studied the effects of IL-4
on apanel ofB lymphocytesfrom 12B-CLL patients . Inno instance did IL-4 syner-
gize with anti-w antibody to supportDNA synthesis. Moreover IL-4 profoundly sup-
pressed the response to IL-2 in the 10 patients responsive to this interleukin . Thus,




12 patients with hematological diagnosis of chronic lymphocytic leukemia were
studied . They were not treated at the time of blood drawing, except patient 11, whose lym-
phocytes were studied at several times before and after initiation of treatment with identical
results. Thepatients'mononuclear cells were >80%v positive for theCD19, CD20, and CD5
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antigens and <10% positive for the CD3 antigen. When membrane Ig could be detected,
monoclonality could be demonstrated on the basis of monotypic light chain expression.
Reagents. mAbs mouse mAb OKT3 (anti-CD3 antigen) and OKM5 were purchased from
Ortho Diagnostic Systems Inc. (Raritan, NJ). The Bl and B4 mAb (anti-CD20 and CD19
antigens, respectively) were obtained from Coulter Immunology (Margency Andilly, France).
The Leu-1 mAb (anti-CD5) was from Becton Dickinson & Co. (Mountain View, CA); the
IOT14 (anti-a chain ofthe IL-2-R CD25) was provided by Immunotech (Marseille Luminy,
France). mAb25 (19) (anti-CD23 antigen) was used at 5 pg/ml final dilution. Insolubilized
rabbit antibody specific for human w chain (anti-u antibody) was purchased from Bio-Rad
Laboratories (Richmond, CH). FITC-conjugated F(ab')z fragment of goat anti-mouse Ig was
from Tago Inc. (Burlingame, CA).
Factors.
￿
rIL-2 was a gift ofBiogen (SA, Geneva, Switzerland). The preparation used had
an estimated activity of 10' U/mg protein and contained 97.3% IL-2 by SDS-PAGE anal-
ysis. IL-4 was obtained from Dr. K. Arai (DNAX Research Institute, Palo Alto, CA) as su-
pernatants from L cells transfected with the peD or PEBT vector containing the human cDNA
clone (13). Some experiments were performed with highly purified L cell-derived IL-4. A
unit of IL-4 was defined as described previously (14). We verified the biological activity of
these IL-4 preparations on normal human B cells; when used at 50-100-U/ml concentrations,
they proved able to induce the expression of the CD23 marker, and to enhance DNA syn-
thesis in the presence of anti-Ii antibody (data not shown). A mock preparation consisting
ofculture supernatants of L cells transfected with a nonrelated cDNA was also used. Recom-
binant human IFN-y was obtained from Roussel Uclaf(Romainville, France). The prepara-
tion had a specific activity of 10' U/mg protein.
Cell Preparations.
￿
B-CLL cells were purified as follows. Mononuclear cells were isolated
from the blood of B-CLL patients by centrifugation on a Ficoll-Hypaque (Pharmacia, Upp-
sala, Sweden) gradient. T cells were eliminated by two cycles of rosetting using aminoethyl-
isothiouronium bromide-treated sheep red blood cells. These preparations were analyzed
using a FAGS TAR flow cytometer. They were homogeneous small cells, contained <0.5%
cells labeled by the OKT3 and by the OKM5 antibodies, and were devoid ofactivation markers
(17).
B Cell Proliferation Assay.
￿
Cells (105) were cultured in flat-bottomed microtest tissue cul-
ture plates (Falcon Labware, Oxnard, CA) in 0.2 ml RPMI-1640 culture medium supplemented
with 1% L-glutamine, 1% antibiotics, 2-ME (0.5 x 10-5 M), and 2 % FCS. The B cell growth
was assayed in two different systems. In the one-step assay, B cells were cultured for 3 d with
anti-g antibody (7 ug/ml) in the presence of IL-2 or IL-4. In the two-step assay, B cells were
cultured alone for 24 and 48 h with IL-2, IL-4, and with both interleukins. Cells were exten-
sively washed and cultured with factors for 3 additional days. Cells were pulsed with 0.5 PCi
of [3Hlthymidine (CEA, Saclay, France) during the last 16 h ofculture period, and incorpo-
ration of [3Hlthymidine was measured by a standard liquid scintillation counter. Cultures
were performed in duplicate and the results were expressed as the mean ofcounts per minute




Cells were cultured for 24 h with various factors and washed twice
before staining. 0.5 x 106 viable cells were treated with antibody at the appropriate dilu-
tion in PBS containing 2 % BSA and a 0.1 % sodium azide (PBSS/BSA/azide). After a 30-min
incubation at 4°C, the cells were washed twice in cold PBS/BSA/azide, resuspended in 50
pl of 1/10 dilution of FITC-conjugated goat F(ab')z anti-mouse Ig, and incubated for 30 min
at 4°C. Thereafter, the cells were washed twice in PBSIBSA/azide and resuspended in PBS/2 %
formaldehyde. Fluorescence analysis was performed on a FRCS TAR flow cytometer.
Results
IL-4 Has No Growth Activity on B-CLL Cells.
￿
B cells from 12 B-CLL patients were
costimulated with anti-w antibody and IL-2 or IL-4. The cells from 10 of these 12




IL-4 Does Not Support DNA Synthesis by B-CLL Lymphocytes
' The response was assessed on day 3 and expressed as cpm .
t In these experiments purified IL-4 was used .
S Cells were cocultured with anti-p antibody (7 pg/ml) and the indicated amounts ofinterleu-
kins, expressed as final U/ml for IL-4 and IL-2 and as final dilutions for mock (these dilu-
tions corresponded to that of 50 and 10 U/ml of IL-4, respectively) .
did IL-4 stimulateDNA synthesis in these conditions . These negative results were
obtained with IL-4 concentrations up to 100 U/ml . Data from six representative pa-
tients among responders and nonresponders to IL-2 are presented in Table I. The
same data were obtainedwhen the response was measuredonday 6 (datanot shown).
In another series ofexperiments, B-CLL cellsfrom three patients were preincubated
with anti-p antibody for 2 d, separated from the insolubilized anti-g antibody, and
cultured for 3 additional days with the same interleukins . Again, IL-4 did not en-
hanceDNA synthesis . The response of anti-g-activated cells was 1,180 f 237 cpm
in the presence of 100 U/ml of IL-4 as compared with 858 t 170 cpm in the absence
of interleukin. The same anti-g-activated cells did respond to IL-2 : 17,327 t 2,545
cpm . Inone additional patient we verified that a 2-d preculture ofB cells with IL-4
(50 U/ml) did not enhance the response to anti-g antibody in a second-step incuba-
tion (data not shown) .
IL-4 Inhibits the Response to IL-2.
￿




presses the response to IL-2. In the
presence of anti-It antibody cells
were cultured with IL-2 (50U/ml),
in the absence or in the presence of
IL-4 (50 U/ml) . Cultures from pa-
tients 1, 3, 4, and 5were performed
with purified IL-4. A cpm was cal-






Medium 305 339 584 519 2,789 622
IL-4 : 100 U/ml 446 586 ND ND 2,104 ND
50 U/ml 395 639 1,083 1,569 1,991 295
10 U/ml 476 860 989 1,314 2,818 332
5 U/ml 358 781 934 1,957 3,725 402
IL-2 : 50 U/ml 25,379 1,078 24,872 42,202 26,243 1,130
10 U/ml 19,983 1,042 17,414 31,602 17,741 899
Mock : 10% vol/vol 458 689 983 ND ND 510
5% vol/vol 432 432 732 43288
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FIGURE 2.
￿
Dose-effect curve of IL-4





fromthree patients were cultured in the
presence of anti-1A antibody + 50
U/ml of IL-2, in the absence ofIL-4,
'~
￿
or in the presence of graded concen-
trations ofIL-4. Results are expressed
i
￿
as percent inhibition by a given con-
centrationofIL-4 (mean t SEM from
'
￿
three patients). The percent ofinhibi-
tion was calculated as follow: Percent
inhibition = 1 - [cpm (cells + IL-4

















(cells + IL-2) - cpm (cells)). The re-
I« (u/mi)
￿
sponses in the absence of IL-4 (ex-
pressed as A cpm) were: 21,866,
33,312, and 30,240.
ofeffect in itself, might interfere with the responsiveness ofB-CLLlymphocytes to
IL-2. Cellsfrom the 10 patients respondingto costimulation byanti-P antibody and
IL-2 were selected. They were cultured for 3 d with anti-p antibody and IL-2 (50
U/ml) in the absence or presence of50 U/ml of IL-4 (Fig. 1). In all instances, IL-4
profoundly inhibited the response to IL-2 (mean suppression: 90 t 2%). These
results were obtained with a purified preparation of IL-4 in four patients (patients
1, 3, 4, and 5)aswell as acrude preparation (the sixotherpatients). Themockprep-
aration had no inhibitory effect in the six patients tested (mean suppression: 3%).
In three patients (patients 3, 4, and 9) the dose-effect curve of IL-4 was estab-
lished. B-CLL lymphocytes were stimulated with anti-p, antibody and 50 U/ml of
IL-2, and the effects of various concentrations of IL-4 were determined (Fig. 2).
The 50% inhibitory concentration of IL-4 corresponded to 1.5 U/ml. An identical
result was obtained when the inhibitory effect of IL-4 was assayed in the presence
of 5 U of IL-2 (data not shown).
Inthe same experimentsDNA synthesis was measured on day 6 in orderto verify
that IL-4 would not delay the response to IL-2. IL-4 inhibited the day 6 response
to the same extent as the day 3 response (data not shown). It should be pointed
TABLE II
IL-4 Suppresses the Response to IL-2 Alone
Cells were cultured with IL-2 (50 U/ml) (without anti-IL antibody) and in the
absence orpresence ofIL-4 (50 U/ml). Results were expressed as cpm on day 3.




1' - 871 3,152
+ 653 654
8' - 548 5,998
+ 441 1,337
10 - 779 7,592




IL-4 Inhibits the Response to the Combination of IL-2 and IFN-y
Cells from patient 11 were cultured in the presence of IFN-'Y (1,000 U/ml) or
anti-p antibody (7 pg/ml). DNA synthesis was measured on day 3. Purified IL-4
was used.
out that IL-4 profoundly suppressed the response to IL-2, regardless ofits magni-
tude, even when this response was low (see Fig. 1). In the same line we verified that
IL-4 did not enhance the response to costimulation with anti-g antibody and IL-2
incells from patients unresponsive to IL-2. The cellsfrompatients2 and 6 (see Table
I) were costimulated with anti-j antibody and IL-2 in the absence or presence of
IL-4. Theirmarginal response to IL-2 was not enhanced by IL-4 (data not shown).
TheInhibitory Effect ofIL-4 Is Observed in theAbsence ofAnti-u Antibody.
￿
The previ-
ously described experiments were performed in the presence ofanti-P antibody as
this reagent is required to obtain an optimal response to IL-2 in most cases ofB-
CLL. However, in some cases IL-2 alone is able to support DNA synthesis. The
cells fromthree patients meetingthis criteria were selected in orderto examine the
interaction between IL-2 and IL-4 in the absence ofother stimulants. Cells from
these patientswere stimulated with IL-2 alone (50U/ml)in the absence orpresence
of50 U/mlofIL-4. As showninTableII, IL-2 didstimulate DNA synthesisin these
cells and this response was fully inhibitedby IL-4. In the sameconditions the super-
natants of 10-d cultures from these patients were examined for the presence of Ig.
In no instance was Ig detected, regardless ofthe presence ofIL-4. We verified that
IL-4 did not affect cell viability. At the end of a 6-d culture of B-CLL cells, the
recovery of viable cells (evaluated by Trypan blue exclusion) was determined and
expressedaspercent oftheinitialcell input. In the presence ofIL-2 (50 U/ml) alone
TABLE IV
Expression of CD25 and CD23 Antigens
' Cells from patient 8 were cultured for 24 h with: medium, 50 U/ml of IL-2,
50 U/ml of purified IL-4, or with both interleukins.







IL-4 15.4 11 .9





IL-2 (50 U/ml) 31,388 7,422
IL-4 (50 U/ml) 489 384
IL-4 + IL-2 815 59290
￿




of IL-2 and IL-4 is necessary for inhi-
bition. Cells from patient 8 were
pretreated for 48 h (they axis) with
medium, 50 U/ml ofIL-2, or 50 U/ml
ofpurified IL-4. Cellswere washed and
cultured for3 additional days . Cultures
were performed with IL-2 (50 U/ml),
IL-4 (50 U/ml), or both interleukins .
the recovery of viable cells was 73%, to be compared with 80% in the presence of
IL-2 (50 U/ml) and IL-4 (50 U/ml).
IL-4 Inhibits the Costimulation by Interferon-y andIL-2.
￿
We previously showed (20)
that IFN-y, although in ourhands unable to supportDNA synthesisby B-CLL cells,
can in some patients enhance the responsiveness to IL-2 . We thus tested whether
IL-4 could inhibit thecostimulation ofB-CLL cells by IL-2 and IFN-y . In the pres-
ence ofIFN-y (1,000 U/ml) or anti-tt antibody, B-CLL cells were cultured with IL-
2, IL-4, and with both interleukins for 3 d . As shown in Table III, in the presence
of IL-4 the response to IL-2 and IFN-y was suppressed to the same extent as that
to IL-2 and anti-g antibody.
IL-4 Can Deliver a Positive Signal to B-CLL Cells.
￿
One of the most clear-cut early
effects of IL-4on restingB lymphocytes is theupregulation of theexpression ofCD23
antigen (16) . We thus wondered whether IL-4 was able to exert such an effect on
B-CLL cells . The cells from patient 8 were selected as they expressed a low, and
potentially upregulation-susceptible, percentage ofCD23+ cells (Table IV) . A 24-h
incubation ofthese cells with IL-4 alone induced a twofold increase in the number
ofCD23 + cells . This effect of IL-4was observed regardless of the presence of IL-2 .
Thus, these two interleukins did not interact for the expression ofCD23 . Similarly
IL-4 did not affect the enhancement of CD25 antigen by IL-2 . The cells from pa-
tient 8 were able to respond to IL-2 in the absence of anti-g antibody (see Table
II). We could thus verify that both effects of IL-4 (on CD23 expression and on the
response to IL-2) couldtake place in the same monoclonal cells . Afterpreincubation
with IL-4, these cells were extensively washed and cultured with IL-2 alone or in
the concomitant presence of IL-2 and IL-4 (Fig . 3) . Again, IL-4 suppressed the re-
sponse to IL-2 . It should be pointed out that the continuous presence of IL-4 was
required for this inhibition to take place : cells pretreated by IL-4 and cultured with
IL-2 alone were fully able to respond to this interleukin . We also verified that pretreat-
ment with IL-2 did not prevent the suppressive effect of IL-4 (Fig . 3, bottom) .
Discussion
IL-4 is an interleukin with pleiotropic effects, acting on multiple targets among
immunocompetent cells (21) . Whether used alone or in combination with anotherKARRAY ET AL.
￿
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signal, IL-4 is able to positively affect several aspects of the B cell response. In view
of the heterogeneity of the B cell response patterns to IL-4, we decided to analyze
the effects of this interleukin on monoclonal B cells, obtained from B-CLL patients.
These cells can respond to several interleukins. They are considered as frozen at
a given differentiation step and could thus exhibit a dissociated responsiveness to
some of the effects of IL-4. They probably arise from a discrete subpopulation of
normal B cells of which they may be representative.
One o£ the most conspicuous effects of Il-4 on human as well as murine B cells
is the enhancement of anti-Ft-induced DNA synthesis (1, 14). In a first series of ex-
periments we tested whetherthis effect could be demonstrated on B-CLLcells. Nega-
tive resultswere obtained with cells from 12 different patients even at IL-4 concen-
trations up to 100 U/ml. We verified that this lack ofresponse wasnotdueto a delayed
peak of DNA synthesis andwas not associated with aterminal differentiation. This
unresponsiveness was apparent in two-step incubation experiments, regardless of
the reagent used initially. It could not be attributed to the inefficiency of the signal
provided by anti-p antibody, as cells from 10 patients did respond to costimulation
with IL-2 and anti-p antibody. Thus, in contrast to normal polyclonal B cells, B-
CLL cells do not respond to anti-p antibody and IL-4 by an increased DNA syn-
thesis. This couldbe linked to themalignanttransformation or couldindicate adifferent
responsiveness of the normal B cell subset from which B-CLL cells arise.
IL-2 is able to enhance DNA synthesis by cells from most B-CLL patients (17,
22, 23). Moreover, in selected patients the effects ofthis interleukin can be enhanced
by IFN-y (22) and/or IFN-a (18). Thus, monoclonal B cells provide suitable targets
to search for synergy between interleukins. We examined the interactions between
IL-4 and IL-2. IL-4 profoundly and constantly suppressed the response to IL-2 in
all patient responders to this interleukin. This effect was obtained with low concen-
trations of IL-4 with a 50% inhibitory concentration of 1.5 U/ml. It was not ob-
served with mock preparations of IL-4, and this effect could be demonstrated with
a preparation of IL-4 purified to homogeneity. It was not attributable to a delayed
DNA synthesis and did not result in terminal differentiation.
These results indicated a negative interaction between IL-4 and IL-2 itself. In-
deed they could be obtained in three different experimental conditions: (a) When
an optimal response to IL-2 was obtained by costimulation with anti-A antibody;
(b) when IL-2 was used alone, in these B-CLL cells able to respond to this inter-
leukin in the absence of first signal (17); and(c)when a synergistic response to IL-2
and IFN-y (20) took place. This latter result is important in view of the previously
reported interaction between IFN-y and IL-4 (14, 16).
This negative interaction between IL-4 and IL-2 was unexpected in view of the
synergy between these interleukins on T cell proliferative response (15). However,
it fits with two recently publishedsets ofdata. IL-4 inhibits thedevelopment ofcyto-
toxic effector cells that occurs in response to IL-2 (24). IL-4 inhibits the growth of
bone marrow-derived pre-Bcells (12). As discussedearlier, B-CLLlymphocytes might
be representive of a minor normal B lymphocyte population exhibiting an unusual
responsiveness to IL-4. This is supported by the observation that IL-4, although
able to enhance DNA synthesis by normal polyclonal B cells, partially suppresses
the IL-2-dependent proliferation of these cells (Defrance, T., et al., manuscript sub-
mitted for publication).92
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Another early effect of IL-4 on normal resting B cells is the upregulation of the
expression of CD23 (16, 25, 26). We thus examined whether this effect could take
place in B-CLL lymphocytes. To address this question we selected cells from one
patient on the basis of the following criteria: (a) These cells expressed low levels of
CD23 andwere thus potentially susceptible to upregulation; and (b)these cells were
responsive to IL-2 in the absence of anti-p antibody, allowing the studyofthe inter-
action between both interleukins. The incubation with IL-4 induced an upregula-
tion of CD23, showing that IL-4 could positively act on these monoclonal B cells.
This contrasted with the profound negative effect of IL-4 on the proliferative re-
sponse of the same cells to IL-2. The relationships between these two effects of IL-4
are not yet understood. The preincubation of B-CLL cells with IL-4 neither pre-
ventstheirsubsequent responsiveness to IL-2 (provided IL-4 is removed) nor inter-
feres with the upregulation of CD25 expression by IL-2 itself (see Table IV). Fur-
ther studies are required to analyze the mechanisms of this negative interaction of
IL-4 and IL-2 on the same target B cell.
Our results have important implications for the definition of the effects of IL-4
on B cells. Subsets of B lymphocytes may be insensitive to the growth-promoting
effect of IL-4. More importantly, IL-4 can counteract the effects of IL-2 on B cell
proliferation. As most B-CLL cells respond in vitro to IL-2, this antagonism should
be taken into account when evaluating the therapeutic perspectives offered by the
use of cytokines in B-CLL patients.
Summary
B cells from patients sufferingfrom B-type chronic lymphocytic leukemia (B-CLL)
are susceptible to the effects of several interleukins. Usingthe cells from 12 different
patients we show that IL-4 does not synergize with anti-p antibody for the enhance-
ment of DNA synthesis. Moreover IL-4 profoundly (90%) suppresses the response
to IL-2 in the 10 patient responders to this interleukin. This suppression occurs whether
IL-2 is used alone, in costimulation with anti-Ft antibody, or in synergy with IFN-y.
In no instance did IL-4 induce terminal differentiation. This negative effect of IL-4
can take place in monoclonal B-CLL cells where IL-4 enhances the expression of
CD23. IL-4 does not interfere with the upregulation of CD25 by IL-2. Thus, IL-4
may display inhibitory effects on the proliferative response ofselected B cell popula-
tions. The antagonism between IL-4 and IL-2 has important implications for the
potential use of cytokines in the management of B-CLL patients.
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